Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia
Copyright © 2023 Elsevier Ltd. All rights reserved..
Use of the potent tyrosine kinase inhibitor imatinib as the first-line treatment in chronic myeloid leukemia (CML) has decreased mortality from 20% to 2%. Approximately 30% of CML patients experience imatinib resistance, however, largely because of point mutations in the kinase domain of the BCR-ABL1 fusion gene. The aim of this study was to use next-generation sequencing (NGS) to identify mutations related to imatinib resistance. The study included 22 patients diagnosed with CML and experiencing no clinical response to imatinib. Total RNA was used for cDNA synthesis, with amplification of a fragment encompassing the BCR-ABL1 kinase domain using a nested-PCR approach. Sanger and NGS were applied to detect genetic alterations. HaplotypeCaller was used for variant calling, and STAR-Fusion software was applied for fusion breakpoint identification. After sequencing analysis, F311I, F317L, and E450K mutations were detected respectively in three different participants, and in another two patients, single nucleotide variants in BCR (rs9608100, rs140506, rs16802) and ABL1 (rs35011138) were detected. Eleven patients carried e14a2 transcripts, nine had e13a2 transcripts, and both transcripts were identified in one patient. One patient had co-expression of e14a2 and e14a8 transcripts. The results identify candidate single nucleotide variants and co-expressed BCR-ABL1 transcripts in cellular resistance to imatinib.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:131 |
|---|---|
| Enthalten in: |
Leukemia research - 131(2023) vom: 01. Aug., Seite 107325 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Martínez-Castillo, Macario [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.08.2023 Date Revised 01.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.leukres.2023.107325 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358040884 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358040884 | ||
| 003 | DE-627 | ||
| 005 | 20231226073908.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.leukres.2023.107325 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1193.xml |
| 035 | |a (DE-627)NLM358040884 | ||
| 035 | |a (NLM)37302352 | ||
| 035 | |a (PII)S0145-2126(23)00590-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Martínez-Castillo, Macario |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.08.2023 | ||
| 500 | |a Date Revised 01.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Use of the potent tyrosine kinase inhibitor imatinib as the first-line treatment in chronic myeloid leukemia (CML) has decreased mortality from 20% to 2%. Approximately 30% of CML patients experience imatinib resistance, however, largely because of point mutations in the kinase domain of the BCR-ABL1 fusion gene. The aim of this study was to use next-generation sequencing (NGS) to identify mutations related to imatinib resistance. The study included 22 patients diagnosed with CML and experiencing no clinical response to imatinib. Total RNA was used for cDNA synthesis, with amplification of a fragment encompassing the BCR-ABL1 kinase domain using a nested-PCR approach. Sanger and NGS were applied to detect genetic alterations. HaplotypeCaller was used for variant calling, and STAR-Fusion software was applied for fusion breakpoint identification. After sequencing analysis, F311I, F317L, and E450K mutations were detected respectively in three different participants, and in another two patients, single nucleotide variants in BCR (rs9608100, rs140506, rs16802) and ABL1 (rs35011138) were detected. Eleven patients carried e14a2 transcripts, nine had e13a2 transcripts, and both transcripts were identified in one patient. One patient had co-expression of e14a2 and e14a8 transcripts. The results identify candidate single nucleotide variants and co-expressed BCR-ABL1 transcripts in cellular resistance to imatinib | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a BCR-ABL1 | |
| 650 | 4 | |a Chronic myeloid leukemia | |
| 650 | 4 | |a Imatinib | |
| 650 | 4 | |a Next-generation sequencing | |
| 650 | 4 | |a Point mutation | |
| 650 | 4 | |a Resistance | |
| 650 | 7 | |a Imatinib Mesylate |2 NLM | |
| 650 | 7 | |a 8A1O1M485B |2 NLM | |
| 650 | 7 | |a Fusion Proteins, bcr-abl |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Nucleotides |2 NLM | |
| 700 | 1 | |a Gómez-Romero, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Tovar, Hugo |e verfasserin |4 aut | |
| 700 | 1 | |a Olarte-Carrillo, Irma |e verfasserin |4 aut | |
| 700 | 1 | |a García-Laguna, Anel |e verfasserin |4 aut | |
| 700 | 1 | |a Barranco-Lampón, Gilberto |e verfasserin |4 aut | |
| 700 | 1 | |a De la Cruz-Rosas, Adrián |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Tovar, Adolfo |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Zavala, Araceli |e verfasserin |4 aut | |
| 700 | 1 | |a Córdova, Emilio J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia research |d 1991 |g 131(2023) vom: 01. Aug., Seite 107325 |w (DE-627)NLM000939560 |x 1873-5835 |7 nnns |
| 773 | 1 | 8 | |g volume:131 |g year:2023 |g day:01 |g month:08 |g pages:107325 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.leukres.2023.107325 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 131 |j 2023 |b 01 |c 08 |h 107325 | ||